Full Press Release Details
Inc. Names Founder and Executive Chairman Hermann
Luebbert as Chief Executive Officer
Mass. (May 30, 2023) - Biofrontera Inc. (Nasdaq: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical
company specializing in the commercialization of dermatologic products, announces that its Board of Directors has named Hermann Luebbert
as Chief Executive Officer. Mr. Luebbert is a founder of the Company and currently serves as Executive Chairman. He will continue to
serve as Chairman of the Board of Directors.
Luebbert founded Biofrontera's former parent company, Biofrontera AG, in 1997 and served as CEO and Managing Director while completing
an initial public offering for Biofrontera AG in Germany and later in the U.S. He served as CEO and Chairman of the Company during the
process of establishing Biofrontera AG's U.S. operations as Biofrontera Inc. The U.S. business subsequently completed its own initial
public offering on Nasdaq in 2021, at which time Mr. Luebbert was named Executive Chairman and shortly thereafter resigned from his position
at Biofrontera AG. Prior to founding Biofrontera AG, Mr. Luebbert spent 10 years in Neuroscience Research at Novartis and was Chair of
the Animal Physiology Department at Ruhr-University Bochum. Mr. Luebbert received a Ph.D. in Biology from the University of Cologne and
completed post-doctoral research at the California Institute of Technology.
look forward to taking a more active, day-to-day role in driving a focused path to profitability, executing tightly against our forecasts
and, in turn, building shareholder value. As CEO, I am committed to transparency regarding our strategic vision and our progress as we
grow Biofrontera more broadly and integrate other value-creating initiatives to support our commercial team," said Mr. Luebbert.
establishing in-house R&D we expect to expand Biofrontera beyond our core strength in sales and marketing, gain greater control over
our future and be better equipped to accelerate ongoing efforts to broaden the market for photodynamic therapy (PDT)," he added.
other strategic initiatives to transform Biofrontera into an integrated pharmaceutical company, Mr. Luebbert is evaluating plans to establish
Biofrontera's own research and development capability. Currently R&D is managed by Biofrontera Bioscience GmbH and funded by
Biofrontera Inc. via a royalty on sales of licensed products, and is limited to predefined clinical trials. The Company will evaluate
R&D costs and relative return as it considers building the infrastructure to manage its own clinical studies, which could support
the expansion of the Ameluz-PDT label into new indications and potentially the development of new products.
also will strengthen our established medical affairs function by our continued support of investigator-initiated research. All of this
will be pursued by starting small and carefully balancing expenses against our growing revenue," continued Mr. Luebbert.
Company's plans include an enhanced focus on pursuing new products and new technologies through acquisitions and licensing transactions,
while maintaining the Company's focus on dermatology and leveraging its commercial expertise.
Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of products for the treatment of dermatologic conditions with
a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic
keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com
and follow Biofrontera on LinkedIn and Twitter.
statements in this press release may constitute "forward-looking statements" within the meaning of the United States Private
Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to
the growth strategy for Biofrontera Inc. (the "Company"), the transition of responsibilities at the Company, 2023 forecasts,
the establishment of and benefits from in-house research and development, efforts to broaden the market for PDT, the expansion of the
Ameluz label, new products, and potential acquisition and licensing transactions. We have based these forward-looking
statements on our current expectations and projections about future events, nevertheless, actual results or events could differ materially
from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties,
many of which are beyond our control, including, but not limited to, the impact of any extraordinary external events; any changes in
the Company's relationship with its licensors; the ability of the Company's licensors to fulfill their obligations to the
Company in a timely manner; the Company's ability to achieve and sustain profitability; whether the current global disruptions
in supply chains will impact the Company's ability to obtain and distribute its licensed products; changes in the practices of
healthcare providers, including any changes to the coverage, reimbursement and pricing for procedures using the Company's licensed
products; the uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical
trials; whether results of earlier clinical trials or trials of Ameluz in combination with BF-RhodoLED
in different disease indications or product applications will be indicative of the results of ongoing or future trials; uncertainties
associated with regulatory review of clinical trials and applications for marketing approvals; whether the market opportunity for Ameluz
in combination with BF-RhodoLED is consistent with the Company's expectations; the Company's ability
to comply with public company requirements; the Company's ability to regain compliance with Nasdaq continued listing standards,
the Company's ability to retain and hire key personnel; the sufficiency of cash resources and need for additional financing and
other factors that may be disclosed in the Company's filings with the SEC, which can be obtained on the SEC website at www.sec.gov.
Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are
made and reflect management's current estimates, projections, expectations and beliefs. The Company does not plan to update any
such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as